MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it ...

Shares in Pliant Therapeutics plunged in after-hours trading after the US biotech revealed that it has paused a phase 2b/3 ...

Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...

Researchers identified three new all-oral drug regimens that include at least one of two new drugs for treatment of ...

Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...

For Tammy Gusher Delgado, 56, the decision to join a clinical trial was clear. With a recent multiple sclerosis diagnosis and a clinical trial offering either the study drug or an approved ...

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered NimodipineNew Drug Application ...

Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

The Scientific Review Committee (SRC) charter is to review the safety data from the patients treated in the Phase I portion ...

In January 2025, Aptose announced the initiation of the TUSCANY trial and dosing in the first cohort of newly-diagnosed AML patients with the lowest starting dose (40 mg) of TUS as part of the ...